Successfully reported this slideshow.
Your SlideShare is downloading. ×

Jim McLaughlin - Intelesens - Univ Ulster - Northern Ireland UK - Stanford Engineering - Feb 25 2013

More Related Content

More from Burton Lee

Jim McLaughlin - Intelesens - Univ Ulster - Northern Ireland UK - Stanford Engineering - Feb 25 2013

  1. 1. Connected Health Research and Innovation at the University of Ulster Professor Jim McLaughlin Director Of the Engineering Research Institute & NIBEC University of Ulster - and Founder of Intelesens Stanford Engineering (ME421) Feb 25 2013
  2. 2. Northern Irish inventors from a population of 1.7 million  1906: Royal Victoria Hospital  1965: Portable defibrillator claims to be the first air- created by Frank Pantridge conditioned public building in  1967: Pulsar discovered by the world. (Sirocco Works) Jocelyn Bell Burnell  Three point linkage, patented  1970s: Positive end- by Harry Ferguson of County expiratory pressure Down – led to early tractors technique for treatment of  Disintegration of an atomic pulmonary contusion - developed by staff at the (splitting the atom) discovered RVH, Belfast by Ernest Walton et al.  Others great achievements:  Ejection seat - first live test of the building of the Titanic a reliable, successful modern (worlds largest ship in 1912), ejection seat developed by the development of the James Martin pneumatic tyre (John Dunlop) and a range of aerospace achievements.
  3. 3. Nanotechnology and Integrated Bioengineering Centre (NIBEC) Engineering Research Institute £30million funding since 2001 EPSRC; BIS; INI; HEA; DEL; SFI; Wellcome MRC; Trust; Leverhulme; EU; R&D Office; NSF (US Irl Industry; Partnership) Philanthropic
  4. 4. Multi-disciplinary research centre applying nanotechnology and bioengineering to the following thrusts:
  5. 5. THE DISTRIBUTION OF ACUTE CORONARY DEATHS The Acute MI Mc NEILLY (BELFAST), 1965-66, 818 DEATHS Myocardial 100 preservation % 100 90 90 100 100 History: 80 80 PERCENTAGE ALIVE PERCENTAGE ALIVE 70 70 60 60 50 50 Average patient Average patient 40 40 response time response time 30 30 20 20 10 10 0 0 0 0 NIBEC founded in 0.1 0.1 HR HR 0.2 0.2 HR HR 1 1 DAY DAY INTERVAL AFTER ONSET INTERVAL AFTER ONSET 7 7 DAY DAY 0 0 1 1 2 2 3 3 Hrs. from symptom onset 4 4 1985 by Professor John Anderson Traced back to Professor Partridges idea of mobile coronary care New building in 1994 and 2004
  6. 6. History of Success in CH
  7. 7. • Engineering • Computing • Sensors, Science Devices, Wireless • AAL, Big Data, Cloud Engineering Computing Science Professor Jim McLaughlin: Ulster Lead Nursing Business • Nursing • Business •Biomedical •Business Models, Science Economic •Sports Science Assessment
  8. 8. Infrastructure  SMART HOME & SMART WARD  SMART Doctors Surgery  SERG : Ambient Assisted Living  Data Analysis/DSP/Labview Project Laboratories  Patient Testing Laboratories  NIBEC: Nanotechnology, Microfluidics; Cell- /Micro- Biology Laboratories; Microfabrication Cleanrooms  Terrace House and Playing Field Testing  Plans for new Innovation Centre (Manufacturing)…Rapid Proto typing
  9. 9. Connected Health Themes at Ulster  Wireless Vital Signs Monitoring  Point of Care Diagnostics Systems  Sensor Technology  M-Health  Ambient Assisted Living  Clinical Trialing  Economic Assessment and Valuation  Technology Transfer…spin outs and licensing  Personalized Medicine (BSRI)  CTRIC and UUM (ISRC)
  10. 10. Connected Health Themes at Ulster Sensor Technology  ECG, EMG, EEG  Biosensors:  SpO2 (Reflective) Glucose and  PWV (piezo) Cardiac Enzymes via IDE’s  Accelerometers (MEMS)  Micro- SPR  Respiration Rate  Micro-Raman  GSR  Micro-E-nose (plasma)  Cardiac Mapping All about higher sensitivity &specificity – less false alerts Micro-E-nose (plasma)
  11. 11. Key research topics  AF sensing/pattern  Pulse Wave recognition Velocity  Sleep Apnoea  Remote Foetal early warning monitoring  Smart MEWS  Hypo- detection in based multi- Diabetics sensing Algorithms  Non Invasive  De-hydration Glucose Sensing Monitoring  NIBP systems  Novel Wearable  Cardiac Mapping Electrode Systems
  12. 12. The NIBEC POC Cardiac Enzyme Impedance
  13. 13. 3. Innovation Wireless Vital Signs Platforms  Intelesens has developed its platform as the basis of OEM products temperature ecg  Short range or cellular telemetry SpO2  Range of vital signs possible  Respiration respiration rate accelerometer  Blood oxygen (late 2007)  Temperature  Motion, activity and falls  Cardiac output  ECG  Compact, light, easy to wear
  14. 14. Ubiquitous surveillance monitoring system  Full ambulation  Wi-Fi connectivity  Simple, easy, unobtrusive, low-cost  Alert management
  15. 15. Atrial Fibrillation captured with Aingeal device Example of CSR captured
  16. 16. Smart: ECG Pattern Recognition  Bradyarrhythmia  Ventricular Tachycardia  Supra Ventricular Tachycardia  Self-terminating Ventricular Fibrillation  Asystole  Atrial Flutter  Atrial Fibrillation  1st Degree Heart Block  2nd Degree Heart Block •Congenital heart defects  3rd Degree Heart Block •Congestive heart failure •Heart muscle disease •Heart valve disorders Clinical Study complete with Ulster Hospital: •Other diseases, such as lung conditions Dr Roy Harper and currently undergoing one at •External forces such as electric shock or severe UI and Dublin chest injury
  17. 17. Heartsine Corporate Headquarters: HeartSine Technologies, Inc. The 1970’s NIBEC Vision 940 Calle Amanecer Suite E San Clemente, CA 92673 United States Phone: 1.949.218.0092 Fax: 1.949.218.0093 Toll Free: 1.866.HRT.SINE European Office: HeartSine Technologies, Ltd. Canberra House 203 Airport Road West Belfast, BT3 9ED Northern Ireland Phone: +44 (0)28 9093 9400 Fax: +44 (0)28 9093 9401
  18. 18. Non-U.S. Only A 360º ECG for a complete view of the heart Touchscreen color monitor Recently acquired by Verathron 80-Lead Technology Benefits:
  19. 19. The Vision – Self Care Model  Sensor – analysis – diagnostics – feedback – immediate therapy Worn Vital  Vital signs alert and Signs Cloud immediate worn therapy Analytics Detection  For example – heart attack and possible patch based TPA delivery Feedback  Or respiration rate and dosage feedback for therapy  Require POC diagnostics and improved drug delivery techniques Worn Drug Therapy
  20. 20. Founder and Managing Director: Dr. Suzanne Roghieh Saffie-Siebert Professor Jim McLaughlin Director and CSO John Hartnett and Tim Brundle (Investors and Directors) Scientists: Drs. Nessim Troabi-Pour; Mukhtar Ahmed; Jeremy Hamill SiSaf scooped a major prize – for development of an innovative drug-delivery system at the Irish Technology Leadership Group’s (ITLG) annual awards ceremony in Silicon Valley, California.
  21. 21. The SiSaf Difference  Solubility – Improved up to 40%  Biocompatibility – Organic Solid Nanoparticles  Active Delivery – Self beneficial compound  Control Release – Tailor made release profile  Penetration – Into and through skin  Absorption – Improved through localization and SR  Localization – High concentrated molecule
  22. 22. Impact of Connected Health @Ulster Professors McLaughlin, Anderson  35 patents, 3 companies and many licences and McAdams have a 25 year  Created over 120 jobs across all 3 Connected history of developing successful Health spin-outs patent exploitation in the area of medical sensors and electro-  Saved lives, improved the quality of life and cut stimulation devices, following the costs. impact that Pantridge, Adgey and  Technologies are used by the Wellcome Trust, Anderson had on mobile coronary CIMIT and various companies as exemplars of the care in Northern Ireland. future of healthcare.  The concept of Connected Health in Northern Ireland was derived from much of our early work. This has inspired many initiatives such as the:  BEST Centre, CHIC, ECHCampus (2009-2012) and now the European Connected Health Alliance (2011-); Their more recent work, with over 35 patents, has been commercialised to companies such as Heartsine Inc., Northern Ireland Connected Health-ECO; culminating Samsung, Intelesens Ltd. Heartscape Inc., Tyco, SHL Telemedicine, Phillips and Air Products. These companies’ with NIMAC which joint agreement between USA, products have now been well established and include the Finland, ROI, Northern Ireland, the Manchester and world’s best selling disposable ecg electrode, telemedicine based 12 lead electrodes, the most compact AED marketed Catalonia; Northern Ireland DHSSPSNI & DETI signing a and a smart wireless chest based ecg, respiration rate, temperature and SpO2 monitor. strategic and joint Connected Health MOU
  23. 23. ECH - Alliance and the new Northern Ireland Connected Health Eco System  “Delivering leadership for the development of Connected and Mhealth markets and practice across Europe and beyond”  Joint MOU between DETI and DOH in Northern Ireland (better health and jobs)  Setting up of a NI CH Eco System – Clinicians- Business- Academia  Strong links with Boston – Finland – Catalonia – Manchester
  24. 24. EU-US eHealth Business Marketplace – Boston USA 2012
  25. 25. The recipe for Connected Health Device Innovation  Good Product design – from concept to scale-up  User needs – cost reduction (evidence) – regulatory  Accurate and flexible business model  A good users based - ECO system (smart market analysis)  Miniaturised and robust technology  Portable – Cloud based solutions – still some security issues  High quality data analytics  Early warning with clear patient & clinical benefits  Smart Back-end systems  And most of all functional & well designed (intuitive) and meets all FDA – CE approvals and easily validated
  26. 26. Conclusion  History of Success  University of Ulster Capability and experience  Strong Clinical Integration  Technology Transfer – spin-outs – CHIC’s future Role  ECHA- The Northern Ireland CH Eco System  Finally - We need a systems and design approach to adopting this new form of delivering Healthcare – with sensors, diagnostics, communications, software, clinical specifications, health economics, regulatory drivers and business models all playing a key role to drive our Healthcare Provision and Economy